65,437 trials
Acute Undifferentiated Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q)
Primary: Treatment Related Mortality Defined as the Percent of Patients no Longer Alive at 60 Days After Registration — 91; 10 Participants
Freeze Dried Plasma in Healthy Volunteers
Primary: Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests — 4; 4; 4; 4 Participants
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
Diabetes Mellitus, Type 2
Primary: Participant Preference Between 2 Injection Devices Based on Global Preference Item — 87.7; 80.6; 2.6; 4.5 percentage of participants — p=<0.0001
Insomnia Disorder
Primary: Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 — -18.9; -32.0; -45.1; -61.4 minutes — p=<0.001
Human Microbiome
Primary: Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization — -4174 fg/uL
Constipation Predominant Irritable Bowel Syndrome
Primary: Adverse Events in >2% Patients — 33; 7; 7; 11 participants
Diabetes
Primary: Reporting of Adverse Events During 12 Week Study Period — 9; 8; 7; 29 Adverse Events
Arrhythmia
Primary: The Percent of Participants Who Were MR Scan-Related ImageReady System Complication -Free — 100 percentage of participants
Atopic Dermatitis
Primary: Percentage of Subjects With Treatment Success at Visit 4/Day 15 — 62; 71; 47; 102 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 85 — 0.115; 0.020 Liters — p=<0.001
Myasthenia Gravis Exacerbations
Primary: Change in Quantitative Myasthenia Gravis (QMG) Scale Score — -6.4 score on a scale — p=<0.001
Glioma
Primary: Number of Patients Who Had 6-month Progression-free Survival. — 3 Participants
Photoaging
Primary: Change in Aesthetics — 2; 1 score on a scale
Advanced Solid Tumors
Primary: Overall Response Based on RECIST V1.1 Following Oral Doses of Pexidartinib (Efficacy Analysis Set) — 0; 0; 1; 0 Number of participants